Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Challenger's Marketable Securities for the quarter that ended in Dec. 2025 was $13,826 Mil.
Challenger's annual Marketable Securities
increased
from Jun. 2023 ($18,514 Mil) to Jun. 2024 ($19,904 Mil) and
increased
from Jun. 2024 ($19,904 Mil) to Jun. 2025 ($20,666 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Challenger Marketable Securities Related Terms
Challenger Marketable Securities Historical Data
* Premium members only.
The historical data trend for Challenger's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of $13,826 Mil mean?
Challenger (CFIGY) has a Marketable Securities of $13,826 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Challenger and its competitors.
Is Challenger's Marketable Securities too high?
Challenger's current Marketable Securities is $13,826 Mil. Overall, Challenger has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Challenger's Marketable Securities compare to AFL and MET?
Challenger's Marketable Securities of $13,826 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for an Insurance company?
A good Marketable Securities depends on the Insurance industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Challenger and its competitors. Challenger's current Marketable Securities is $13,826 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Challenger stock overvalued right now?
Challenger (CFIGY) has a current Marketable Securities of $13,826 Mil. The stock's GF Value™ is $16.42, compared to a current price of $43.70 — trading 166.1% above its estimated fair value. The current Marketable Securities is $13,826 Mil. Challenger's overall GF Score™ is 55/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Challenger (CFIGY), the current Marketable Securities is $13,826 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Challenger (CFIGY) Overvalued in 2026?
Based on GuruFocus' analysis, Challenger stock appears to be overvalued.
The current stock price of $43.70 is trading 166.1% above its estimated GF Value™ of $16.42.
Key valuation signals for CFIGY:
Marketable Securities: $13,826 Mil
GF Value™: $16.42 vs. price of $43.70 (166.1% above fair value)
No single metric tells the full story. See the CFIGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Challenger's core business is selling annuity products in the Australian retirement market and, since November 2016, selling Australian dollar-denominated annuities into Japan's large retirement market. The firm's annuity products provide investors guaranteed regular payments over an agreed term for an upfront lump sum investment and is designed primarily to protect investors from the longevity risk of outliving their savings. Challenger also operates a funds management business, Fidante Partners, which has minority stakes in several boutique global investment managers, and Challenger Investment Management, which primarily manages investments supporting its annuities business.
55GF Score
Get the complete analysis for CFIGY
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CFIGY has been successfully added to your 
